This association implies that the phenotypes seen during cystic fibrosis may lead to IBD and thus provides clinical support for a model where increased goblet cells and mucin in patients undergoing anti-TNF therapy exacerbates inflammation and IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.